Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 8 Best Debt Free Stocks to Buy Right Now. On March 24, 2026, ...
Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoidApproval in ...
Sanofi and Regeneron's Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid Approval in moderate-to-severe patients was based on pivotal study results show ...
Sanofi & Regeneron’s Dupixent receives Japanese marketing approval to treat adults with moderate-to-severe bullous pemphigoid: Paris Wednesday, March 25, 2026, 09:00 Hrs [IST] T ...
Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained disease remission through Week 36 compared with placebo ...
Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained ...
Sanofi and Regeneron announced that Japan’s Ministry of Health, Labour and Welfare has approved Dupixent (dupilumab) for ...
Regeneron Pharmaceuticals is back in focus after a refreshed valuation framework lifted the modelled fair value estimate from ...
Apogee Therapeutics has published phase 2 eczema data that suggest its anti-IL-13 antibody is a threat to Eli Lilly, ...
Connect Biopharma has reported 52-week improvements across multiple endpoints in a phase 3 trial of its eczema drug candidate, fueling the biotech’s belief that its molecule is ...
In this video, Brian S. Kim, MD, discusses the management of patients with severe chronic spontaneous urticaria.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results